±è°æ¼ö
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : ´ç´¢º´/°©»ó¼±Áúȯ/ÁöÁú´ë»çÁúȯ/¼º¼±Áúȯ/±âŸ ³»ºÐºñ´ë»çÁúȯ
Á÷
ˤ
: ºÎ±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
29
ÇØ¿Ü
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
28
ÇØ¿Ü
Cardiovascular risk of gestational diabetes mellitus
27
ÇØ¿Ü
Umbilical Cord Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 cell
26
ÇØ¿Ü
Letter: The Risk of Diabetes on Clinical Outcomes in Patients with Coronavirus Disease 2019: A Retrospective Cohort Study (Diabetes Metab J 2020;44:405-13).
25
ÇØ¿Ü
Vitamin D deficiency at mid-pregnancy is associated with a higher risk of postpartum glucose intolerance in women with gestational diabetes mellitus
24
ÇØ¿Ü
Restoration of Cellular Proliferation and Characteristics of Human Tenocytes by Vitamin D
23
ÇØ¿Ü
Sodium-Glucose Cotransporter 2 Inhibitors: Mechanism of Action and Various Effects
22
ÇØ¿Ü
Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158-73).
21
ÇØ¿Ü
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
20
ÇØ¿Ü
Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
1
2
3
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729